- Conditions
- Type 2 Diabetes
- Interventions
- dapagliflozin, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 59
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Aging, Functional Decline
- Interventions
- Dapagliflozin 10Mg Oral Tablet, Semaglutide oral, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2031
- U.S. locations
- 5
- States / cities
- San Antonio, Texas
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 23
- States / cities
- Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more
- Conditions
- Physical Activity
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Acute Heart Failure, Heart Failure
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The TIMI Study Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 114
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
- Conditions
- Chronic Kidney Disease
- Interventions
- AZD5718, Dapagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Canoga Park, California • La Mesa, California • San Carlos, California + 19 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
- Interventions
- Dapagliflozin 10 mg, Placebo tablet
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 17,190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 234
- States / cities
- Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
- Conditions
- Type1diabetes
- Interventions
- Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Saxagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Exenatide, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 28
- States / cities
- Tempe, Arizona • Encino, California • Fresno, California + 24 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Dapagliflozin placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 24 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 15
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 11 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Zibotentan, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 50
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Downey, California + 44 more
- Conditions
- Liver Cirrhosis
- Interventions
- Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo for dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo-matching dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Metformin, Placebo
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dulaglutide, Placebo, SGLT2 inhibitor, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Encino, California • Huntington Park, California • Los Angeles, California + 9 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lewy Body Dementia, Parkinson Disease
- Interventions
- Sitagliptin, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Dapagliflozin placebo, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more